Indefinite Delivery Contract 75D30123D16647
Award Date
6/14/23
Last Date to Order
6/6/24
Federal Agency
CDC Pittsburgh
Awardee
Moderna US, Inc.
Ultimate Awardee
Modernatx, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide pediatric COVID-19 vaccines. The contract has a ceiling value of $153,890,500 and a period of performance ending on May 31, 2026. Moderna US, Inc., a subsidiary of Modernatx, Inc., is a biotechnology company that specializes in developing and manufacturing mRNA therapeutics and vaccines. The company has received multiple federal contract awards to supply...
This federal contract IDV award was issued by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide COVID-19 pediatric vaccines. The multiple-award IDV has a total ceiling value of $240,548,000 and a period of performance ending on September 30, 2025. Moderna US, Inc. is the prime contractor for this award, which was not set aside for any specific socioeconomic category. The contract aims to procure COVID-19 pediatric vaccines to support the CDC's preparedness and...
The Centers for Disease Control and Prevention (CDC), a civilian federal agency, awarded a multiple award indefinite delivery contract to Moderna US, Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $408,050,000 and a period of performance ending June 6, 2024. The contract was awarded without any set-aside designations. Under this IDIQ contract, Moderna will deliver standard commercial COVID-19 vaccines with an adult indication (age 19 and older) to the CDC's...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc. for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children aged 0 through 18 years. The contract has a $1,075,250,000.00 ceiling value and a performance period ending on June 6, 2024. The vaccines procured under this multiple-award IDC will support pediatric immunization programs through the Vaccines...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $19,855,000 and a period of performance from June 1, 2025 to May 31, 2026. Moderna US, Inc. is a subsidiary of the parent company Modernatx, Inc., both of which are for-profit organizations specializing in the manufacture of pharmaceutical goods, including mRNA therapeutics and vaccines. Under...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, for the procurement of pediatric COVID-19 vaccines. The contract has a total ceiling value of $1,009,243,769 and a period of performance from June 1, 2025, through May 31, 2026. The primary objective of this IDC is to provide the CDC with a reliable source for pediatric COVID-19 vaccines to support the Vaccines for Children (VFC)...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a global pharmaceutical manufacturer, to provide COVID-19 pediatric vaccines. The contract has a ceiling value of $1,096,801,491.00 and a period of performance running through September 30, 2025. As the prime contractor, Pfizer will deliver a range of critical pharmaceutical products to support various federal healthcare programs, including the Vaccines for Children (VFC)...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $1,517,947,500.00 and a period of performance from April 1, 2022 through March 31, 2023. It is a multiple award contract vehicle that will provide up to 23 standard pediatric vaccines to support CDC's Immunization Awardees and the Vaccines for...
This federal contract IDV award was issued by the Centers for Disease Control and Prevention (CDC) to procure pediatric vaccines for the Vaccines for Children (VFC) program. The 5-year, $1.35 billion multiple award contract aims to purchase standard commercial pediatric vaccines to support immunization efforts for eligible children, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or have insurance that does not cover vaccines. The prime contractor,...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc., a biotechnology company that develops and produces recombinant protein nanoparticle vaccines. The $116 million contract is to provide pediatric COVID-19 vaccines if regulatory approval is obtained. The IDC is a multiple award vehicle, meaning there are multiple contractors that can compete for individual task orders. The period of performance runs through June 6, 2024....